Celularity Inc. Reports $19.8 Million Net Loss and 22.2% Revenue Decline in Q1 2025

Celularity Inc. reported a net loss of $19.8 million for the three months ended March 31, 2025, compared to a loss of $22.0 million for the same period in 2024. The company's total revenues decreased by 22.2% to $11.4 million, down from $14.7 million in the prior year. This decline was primarily driven by a 29.8% drop in product sales, which fell to $9.0 million, largely due to reduced sales of Biovance 3L, although this was partially offset by increased sales of the Rebound product. Service revenues increased by 9.4% to $1.4 million, while license and royalty revenues rose significantly by 81.5% to $1.0 million.

Operating expenses for the first quarter of 2025 were $21.9 million, a slight decrease from $22.1 million in the previous year. The cost of revenues surged by 117% to $3.6 million, influenced by a write-off of capitalized bulk material costs and a shift in product mix. Research and development expenses decreased by 36.2% to $3.7 million, reflecting reduced lab supply costs and personnel expenses. Selling, general, and administrative expenses remained relatively stable, increasing by 1.7% to $14.3 million.

In terms of strategic developments, Celularity completed the acquisition of Sequence LifeScience's Rebound™ product in October 2024, which is expected to enhance its portfolio of placental-derived biomaterials. The company is also actively pursuing opportunities in the cell therapy market, particularly in states like Florida, where new legislation allows for the administration of stem cell treatments. As of March 31, 2025, Celularity had 23.9 million shares of Class A common stock outstanding, reflecting an increase from 22.5 million shares at the end of 2024.

Operationally, Celularity is facing significant challenges, including an accumulated deficit of $919.5 million and ongoing liquidity concerns. The company reported cash and cash equivalents of $0.3 million as of March 31, 2025, and has indicated that it will need to secure additional capital to fund its operations and meet its obligations. The company is currently under a forbearance agreement regarding its debt and is working to regain compliance with Nasdaq listing requirements after failing to file timely reports.

Looking ahead, Celularity's management has expressed uncertainty about its ability to continue as a going concern without securing additional funding. The company is exploring various financing options, including equity offerings and collaborations, to support its ongoing operations and development efforts. The outlook remains cautious as the company navigates its financial challenges while aiming to advance its product pipeline and expand its market presence.